-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sporadic inclusion body myositis (IBM) is an inflammatory and degenerative myopathy of unknown etiology, first discovered in 1978.
Although experimental activities continue to increase, this article also has new progress in understanding of IBM, but because there are currently no licensed treatments, there is a lack of evidence for effective treatment.
This study is a combination of data from three prospective natural history studies of three major neuromuscular units, and is the largest prospective IBM observational study to date.
Using IBM Function Rating Scale (IBMFRS), 181 patients were subjected to manual muscle test (MMT), quantitative muscle test (QMT) and disability score.
This figure illustrates the baseline (A) manual muscle test (MMT) score and (B) the standardized maximum voluntary isometric contraction test score for a single muscle group of 155 and 82 IBM patients, respectively
Predicted percentage change in manual muscle test (MMT) scores
The changes in MMT, QMT and IBMFRS scores over time decreased by an average of 3.
This prospective observational study represents the largest IBM cohort to date.
The measurement values of the patient’s disease progression evaluated in this study accurately predict disease progression in a reliable and useful way, and can be used in trial design SanghaG ,YaoB ,LunnD SanghaG Sangha YaoB Yao LunnD Lunn , et al bmj.
Leave a message here
